First Trust Advisors
HUMA icon

First Trust Advisors’s Humacyte HUMA Stock Holding History

First Trust Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-340,552
Closed -$1.72M – 2574
2024
Q4 		$1.72M Buy
+340,552
New +$1.69M ﹤0.01% 1866

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

First Trust Advisors's HUMA Position: Q1 2025 in Review

First Trust Advisors sold out of Humacyte (HUMA) in Q1 2025, closing a stake of 340,552 shares — an estimated $1.72M sold.

First Trust Advisors first reported a position in HUMA in Q4 2024 and held it in 1 quarter. The position peaked at $1.72M in Q4 2024. 168 funds tracked by Wall St. Rank hold HUMA as of Q1 2025.

  • First Trust Advisors reported no remaining Humacyte position as of Q1 2025 after selling out during the quarter.
  • First Trust Advisors sold 340,552 Humacyte shares in Q1 2025, an estimated $1.72M.
  • First Trust Advisors first reported a position in Humacyte in Q4 2024 and held it in 1 quarter.
  • First Trust Advisors's Humacyte position peaked at $1.72M in Q4 2024.
  • 168 funds tracked by Wall St. Rank held Humacyte as of Q1 2025.

Based on First Trust Advisors's 13F filing for Q1 2025, filed 14 May 2025.